CREB1 and viral infectious disease: Similarly, we treated the LV-VP16-CREB-GFP-infected mice at d 7 after virus infection with NAN-190 (i.p., 0.3 mg/kg/d × 21d), a selective 5-HT1aR antagonist, and performed the NSF and EPM tests at 24 h after the last NAN-190 injection.